<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03036709</url>
  </required_header>
  <id_info>
    <org_study_id>SEARCH 024/RV397</org_study_id>
    <nct_id>NCT03036709</nct_id>
  </id_info>
  <brief_title>Safety and Therapeutic Efficacy of mAb VRC01 During ATI in Early Treatment During Acute HIV Infection</brief_title>
  <official_title>Safety and Therapeutic Efficacy of the Broadly Neutralizing HIV-1 Specific Monoclonal Antibody VRC01 During Analytic Treatment Interruption in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nittaya Phanuphak, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South East Asia Research Collaboration with Hawaii</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo-controlled clinical trial of VRC01 administration and analytic treatment
      interruption (ATI) in adults who began antiretroviral therapy (ART) during early acute HIV
      infection (Fiebig stage I to III). Eligible volunteers will be randomized in a 3:1 ratio to
      either VRC01 or placebo, with randomization stratified by Fiebig stage. Volunteers who are
      receiving ART with a non-nucleoside reverse transcriptase inhibitor (NNRTI) will undergo 4
      weeks of protease inhibitor (PI) substitution for their NNRTI prior to randomization. ATI
      will begin the day of the first dose of either VRC01 or placebo. Participants will be
      monitored closely for HIV viremia and other pre-defined criteria for ART resumption.
      Administration of the study agent (VRC01) every three weeks will be discontinued after 24
      weeks or if ART is resumed, whichever occurs first. Volunteers who remain virally suppressed
      without laboratory or clinical indication for ART resumption at 24 weeks will continue
      intensive monitoring for ART resumption criteria for an additional 24 weeks, during which
      time no VRC01 or placebo will be administered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study agent, VRC-HIVMAB060-00-antibody (AB), was manufactured for the VRC by the Vaccine
      Pilot Plant operated by Leidos Biomedical Research, Inc, formerly SAIC-Frederick, Inc,
      Frederick, MD. Specific manufacturing information is included on the product vial labels and
      Certificates of Analysis and can be found in the Investigator's Brochure (IB). Quality
      Assurance (QA) lot release testing by the manufacturer and ongoing stability programs verify
      conformance to product specifications prior to use in clinical trials.

      VRC-HIVMAB060-00-AB (VRC01) is a broadly neutralizing human monoclonal antibody (mAb)
      targeted against the HIV-1 CD4 binding site. It was developed by the VRC/NIAID/NIH. VRC01 is
      of the IgG1 subtype and is highly somatically mutated from its germ-line precursor. The heavy
      chain CDR3 region is 14 amino acids long, which is an average length relative to natural
      antibodies, and the glycosylation pattern is derived from its production in a Chinese Hamster
      Ovary (CHO) mammalian cell line.

      This is a placebo-controlled clinical trial of VRC01 administration and ATI in adults who
      began ART during early acute HIV infection (Fiebig stage I to III). Eligible volunteers will
      be randomized in a 3:1 ratio to either VRC01 or placebo. Participants will undergo
      randomization stratified by Fiebig stage. Volunteers who are receiving ART with an NNRTI will
      undergo 4 weeks of PI substitution prior to randomization. ATI will begin the day of the
      first dose of either VRC01 or placebo. Participants will be monitored closely for HIV viremia
      and other pre-defined criteria for ART resumption. Administration of the study agent (VRC01)
      every 3 weeks will be discontinued after 24 weeks or at the time ART resumed, whichever
      occurs first. Volunteers who remain virally suppressed without laboratory or clinical
      indication for ART resumption at 24 weeks will continue intensive monitoring for ART
      resumption criteria for an additional 24 weeks, during which time no VRC01 or placebo will be
      administered. Clinical study visits will take place at the Thai Red Cross AIDS Research
      Centre, and the optional procedures may occur at the King Chulalongkorn Memorial Hospital.

      This study will recruit 24 adults aged 20-50 years who were diagnosed during acute HIV
      infection (Fiebig stage I to III) and initiated on ART in Bangkok, Thailand. Participants
      will be recruited from protocol RV 254 (SEARCH 010, WRAIR 1494). This ongoing parent study
      cohort enrolls participants with documented acute HIV infection at the Thai Red Cross AIDS
      Research Center in Bangkok, Thailand. All participants in RV 254 are offered ART at the time
      of enrollment through a separately funded protocol.

      Study agent:

      VRC01 will be administered at a dose of 40 mg/kg intravenously every three weeks to
      participants assigned to the intervention arm of the trial for a total duration of 24 weeks
      or until ART resumption criteria are met, whichever comes first.

      Placebo:

      Normal saline (Sodium Chloride for Injection USP, 0.9%) will be administered intravenously
      every three weeks to participants assigned to the placebo arm of the trial for a total
      duration of 24 weeks or until ART resumption criteria are met, whichever comes first.

      ANALYTIC TREATMENT INTERRUPTION (ATI) Analytic treatment interruption will begin on the day
      of administration of the first dose of either VRC01 or placebo. During the ATI, participants
      will be monitored closely for clinical and laboratory indications to resume ART. These
      criteria are designed to protect the subjects from clinical, immunological, or virological
      adverse effects during the ATI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virologic control (HIV RNA &lt;50 copies/mL) at 24 weeks after analytic treatment interruption (ATI)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The rate of virology control will be compared between treatment groups using a two-sided exact unconditional test with a significance level of 0.05.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the number and percentage of subjects experiencing any serious adverse event (SAE), adverse event (AE), or reactogenicity</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>To assess safety will be tallied by treatment group and presented along with two-sided exact 95% confidence intervals for the proportion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to viral rebound</measure>
    <time_frame>through 48 weeks</time_frame>
    <description>- Time to viral load rebound will be described using a Kaplan-Meier estimator to account for possible censoring and compared between treatment groups using an exact log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of rebound viremia after cessation of ART</measure>
    <time_frame>through 48 weeks</time_frame>
    <description>- Number of HIV RNA copies at the time of rebound viremia will be described using medians and interquartile ranges and compared between treatment groups using a Wilcoxon-Rank Sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ART resumption for any reason after cessation of ART</measure>
    <time_frame>baseline through 48 weeks</time_frame>
    <description>will be described using a Kaplan-Meier estimator to account for possible censoring and compared between treatment groups using an exact log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detectable HIV RNA via single copy assay</measure>
    <time_frame>baseline through 48 weeks</time_frame>
    <description>Quantitative HIV RNA will be described using medians and interquartile ranges at baseline, week 24, and week 48 for subjects with HIV RNA &lt;50 copies/mL by standard PCR. Change from baseline will be compared between treatment groups using a Wilcoxon-Rank Sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T cell count change</measure>
    <time_frame>baseline through 48 weeks</time_frame>
    <description>CD4 count will be described using medians and interquartile ranges at baseline, week 24, and week 48. Change from baseline at week 24 and week 48 will be compared between treatment groups using a Wilcoxon-Rank Sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-associated HIV RNA and DNA in the peripheral compartment</measure>
    <time_frame>baseline through 48 weeks</time_frame>
    <description>will be described using medians and interquartile ranges at baseline, week 24, and week 48. Change from baseline at week 24 and week 48 will be compared between treatment groups using a Wilcoxon-Rank Sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological battery performance at weeks 24 and 48, as compared to baseline at week 0.</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>will be summarized using z-scores based on age-matched normative data when such data is available or as raw scores when not available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of hospitalization</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of hospitalizations can be compared between groups using a Wilcoxon-Rank Sum test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects experiencing a hospitalization</measure>
    <time_frame>48 weeks</time_frame>
    <description>proportion of subjects experiencing a hospitalization will be compared using an exact unconditional test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-AIDS related conditions</measure>
    <time_frame>48 weeks</time_frame>
    <description>Incidence of non-AIDS related conditions can be compared between groups using a Wilcoxon-Rank Sum test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects experiencing a non-AIDS related conditions</measure>
    <time_frame>48 weeks</time_frame>
    <description>proportion of subjects experiencing a non-AIDS related conditions will be compared using an exact unconditional test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>VRC-HIVMAB01060-00-AB (VRC01)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VRC01 is a monoclonal antibody directed towards the site of CD4 attachment on the HIV-1 gp120 envelope (Env) glycoprotein.
VRC01 will be administered at a dose of 40 mg/kg intravenously every three weeks to participants assigned to the intervention arm of the trial for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Chloride for Injection USP, 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline (Sodium Chloride for Injection USP, 0.9%) will be administered intravenously every three weeks to participants assigned to the placebo arm of the trial for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VRC-HIVMAB01060-00-AB (VRC01)</intervention_name>
    <description>VRC01 will be administered at a dose of 40 mg/kg intravenously every 3 weeks for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first.
The first dose of VRC01 will be administered on the same day that antiretroviral therapy (ART) is interrupted. In the simian model, VRC01 administered intravenously achieved peak serum levels within one hour of infusion and was slowly metabolized with an average half-life of 7.61 days.The second infusion of VRC01 will occur at the midpoint of this highest risk period.</description>
    <arm_group_label>VRC-HIVMAB01060-00-AB (VRC01)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium Chloride for Injection USP, 0.9%</intervention_name>
    <description>Normal saline (Sodium Chloride for Injection USP, 0.9%) will be administered intravenously every three weeks to participants assigned to the placebo arm of the trial for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first.</description>
    <arm_group_label>Sodium Chloride for Injection USP, 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to provide written informed consent or, in the case of illiteracy,
             witnessed verbal informed consent with documentation of a thumbprint in lieu of a
             signature.

          -  Passes Test of Understanding

          -  Man or woman aged 20-50 years.

          -  Initiated on ART during acute HIV infection (Fiebig Stage I to III at RV 254
             enrollment).

          -  Prescribed ART for at least 24 months prior to enrollment.

          -  HIV-1 RNA &lt; 50 copies/mL on at least three consecutive measurements within the past 12
             months.

          -  Integrated HIV DNA in PBMCs below the level of detection (1 copy/105 PBMCs) within 6
             months prior to enrollment.

          -  Last documented peripheral blood CD4 &gt;400 cells/mm3 within 3 months prior to
             enrollment.

          -  No HIV-related or AIDS-defining illness within 6 months prior to enrollment.

          -  In general good health

          -  Able to participate in study visits.

        Female-specific Criteria:

          -  Agrees not to become pregnant from the time of study enrollment until the last study
             visit. If a woman is sexually active and has no history of hysterectomy or tubal
             ligation or menopause, she must agree to use a prescription birth control method or a
             barrier birth control method.

          -  Negative Î²-HCG (human chorionic gonadotropin) pregnancy test (urine or serum) on day
             of enrollment for any women unless she is post-menopause for 24 consecutive months or
             has undergone a surgical procedure that precludes pregnancy

        Exclusion Criteria:

          -  Previous receipt of humanized or human monoclonal antibody whether licensed or
             investigational.

          -  Ongoing AIDS-related opportunistic infection (including oral thrush).

          -  Active injection drug use within previous 12 months.

          -  History of a severe allergic reaction with generalized urticaria, angioedema or
             anaphylaxis in the 2 years prior to enrollment.

          -  History of chronic urticaria requiring daily treatment.

          -  Physical finding on examination considered indicative of significant disease such as
             murmur (other than functional), hepatosplenomegaly, or focal neurologic deficit.

          -  Hypertension that is not well controlled by medication.

          -  Hepatitis B surface antigen positive at any time in the past.

          -  Hepatitis C antibody positive at any time in the past.

          -  Untreated syphilis

          -  Estimated GFR &lt; 50 ml/min within the past 90 days.

          -  Pregnant or breast-feeding.

          -  Receipt of licensed vaccine or other investigational study agent within 28 days prior
             to enrollment or past participation in an investigational HIV vaccine study with
             receipt of active product.

          -  Current or planned participation in another interventional clinical trial during the
             study period.

          -  Chronic or recurrent use of medications that modify host immune response, e.g., oral
             or parenteral steroids, cancer chemotherapy.

          -  Any other chronic or clinically significant medical condition that in the opinion of
             investigator would jeopardize the safety or rights of the volunteer. Including, but
             not limited to: diabetes mellitus type I, chronic hepatitis, renal failure; OR
             clinically significant forms of: drug or alcohol abuse, mental illness, severe asthma,
             autoimmune disease, psychiatric disorders, heart disease, or cancer.

          -  Study site employee.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nittaya - Phanuphak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South East Asia Research Collaboration with Hawaii</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nittaya - Phanuphak, MD, PhD</last_name>
    <phone>+6622542566</phone>
    <email>nittaya.p@trcarc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nitiya - Chomchey, MSc</last_name>
    <phone>+6622542566</phone>
    <phone_ext>111</phone_ext>
    <email>nitiya.c@searchthailand.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SEARCH</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nittaya - Phanuphak, MD, PhD</last_name>
      <phone>+6622542566</phone>
      <email>nittaya.p@trcarc.org</email>
    </contact>
    <contact_backup>
      <last_name>Nitiya - Chomchey, MSc</last_name>
      <phone>+6622542566</phone>
      <phone_ext>111</phone_ext>
      <email>nitiya.c@searchthailand.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2017</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>South East Asia Research Collaboration with Hawaii</investigator_affiliation>
    <investigator_full_name>Nittaya Phanuphak, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

